AU2024200948B2 — Methods for treating or preventing ophthalmological conditions
Assigned to Astellas US LLC · Expires 2025-09-11 · 1y expired
What this patent protects
#$%^&*AU2024200948B220250911.pdf##### ABSTRACT The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination …
USPTO Abstract
#$%^&*AU2024200948B220250911.pdf##### ABSTRACT The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof. ABSTRACT The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof. 20 24 20 09 48 14 F eb 2 02 4 A B S T R A C T T h e p r e s e n t i n v e n t i o n r e l a t e s t o m e t h o d s f o r t r e a t i n g a n d p r e v e n t i n g o p h t h a l m o l o g i c a l d i s e a s e a n d d i s o r d e r s , c o m p r i s i n g a d m i n i s t e r i n g A n t a g o n i s t A o r a n o t h e r p h a r m a c e u t i c a l l y a c c e p t a b l e 2 0 2 4 2 0 0 9 4 8 1 4 F e b 2 0 2 4 s a l t t h e r e o f , o p t i o n a l l y i n c o m b i n a t i o n w i t h a n o t h e r t r e a t m e n t , t o a s u b j e c t i n n e e d t h e r e o f . T h e p r e s e n t i n v e n t i o n a l s o r e l a t e s t o m e t h o d s f o r t r e a t i n g a n d p r e v e n t i n g o p h t h a l m o l o g i c a l d i s e a s e a n d d i s o r d e r s , c o m p r i s i n g a d m i n i s t e r i n g a n a n t i - C 5 a g e n t ( e . g . , A R C 1 9 0 5 ) , o p t i o n a l l y i n c o m b i n a t i o n w i t h a n o t h e r t r e a t m e n t , t o a s u b j e c t i n n e e d t h e r e o f .
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.